Back
ESC Professional Premium Access

Echocardiographic characterization of patients with supranormal ejection fraction: pooled core laboratory analysis of the TOPCAT and PARAGON-HF trials

Session: Insights from recent HFpEF trials 1
Topic: Epidemiology, Prognosis, Outcome
Speaker: Doctor X. Wang (Boston, US)
Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Xiaowen Wang

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
0 follower

5 more presentations in this session

Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial

Speaker: Doctor S. Chatur (Boston, US)

Access
Abstract
Slides
Video
Thumbnail

Dietary sodium intake and outcomes: a secondary analysis from SODIUM - HF

Speaker: Professor C. Saldarriaga (Medellin, CO)

Access
Abstract
Slides
Video
Thumbnail

Mediators of the benefit of sotagliflozin in patients with worsening heart failure in SOLOIST-WHF

Speaker: Professor B. Pitt (Ann Arbor, US)

Access
Abstract
Slides
Video
Thumbnail

Influence of background therapy on efficacy of dapagliflozin in patients with heart failure and improved ejection fraction

Speaker: Doctor M. Pabon (Boston, US)

Access
Abstract
Slides
Video
Thumbnail

Effects of empaglifozin on collagen biomarkers in patients with heart failure. Results from the EMPEROR trials

Speaker: Doctor M. Sumin (Mainz, DE)

Access
Abstract
Slides
Video
Thumbnail

Access the full session

Insights from recent HFpEF trials 1

Speakers: Doctor X. Wang, Doctor S. Chatur, Professor C. Saldarriaga, Professor B. Pitt, Doctor M. Pabon...
Access
Video
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb